Patent: 9,957,480
✉ Email this page to a colleague
Summary for Patent: 9,957,480
| Title: | T cell receptor-deficient T cell compositions |
| Abstract: | The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same. |
| Inventor(s): | Sentman; Charles L. (West Lebanon, NH) |
| Assignee: | THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) |
| Application Number: | 14/934,256 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,957,480 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,957,480
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Emergent Biodefense Operations Lansing Llc | BIOTHRAX | anthrax vaccine adsorbed | Injection | 103821 | 11/12/1998 | ⤷ Try a Trial | 2029-10-29 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
